Biotech Essentials

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 13.05.2021.

#RWE
#JJDC
#startups
#biotech
#GoodDayBIO

Startups

@ForbesTech shared
On May 11, 2021
RT @Forbes: Ginkgo Bioworks to go public in $17.5 billion deal with Hollywood exec Harry Sloan’s SPAC https://t.co/oPJHoz9fIv https://t.co/YsB47KlNVw
Open
Ginkgo Bioworks To Go Public In $17.5 Billion Deal With Hollywood Exec Harry Sloan’s SPAC

Ginkgo Bioworks To Go Public In $17.5 Billion Deal With Hollywood Exec Harry Sloan’s SPAC

Synthetic biology pioneer Ginkgo Bioworks agreed to go public in a $17.5 billion SPAC deal.

@rtnarch shared
On May 8, 2021
RT @PeterKolchinsky: My friend @daphnezohar posts heartfelt, EXPERT advice for Congress. She & her team actually invent medicines that give us hope. As a https://t.co/hkiKXC7taQ’s Life Science Builder (not Landlord), she’s on side of good & can guide to how to fix the bad. https://t.co/yFXrHfq42F
Open
Congress, These Are The Right Problems But The Wrong Solutions. Don’t Make The Mistake Of Killing The Innovation That Brings New Medicines And Jobs.

Congress, These Are The Right Problems But The Wrong Solutions. Don’t Make The Mistake Of Killing The Innovation That Brings New Medicines And Jobs.

This was the third time in just the past few months that politicians sought to intervene in the biopharma industry with policy proposals that betrayed a deep misunderstanding of the complex ...

@FierceBiotech shared
On May 10, 2021
“[The larger fund] really just allows us to participate,” said Tim Haines, chairman and managing partner at Abingworth. https://t.co/kV9SMt2cj4
Open
Abingworth raises $582M clinical co-development fund amid rising biotech interest

Abingworth raises $582M clinical co-development fund amid rising biotech interest

Abingworth has raised $582 million for its second clinical co-development fund. The fund, ACCD 2, equips Abingworth to make triple-digit million investments in late-stage clinical programs.

@MNakada shared
On May 11, 2021
@aetioninc industry leader in the #RWE space closes $110M Series C Funding Round Led by Warburg Pincus https://t.co/OGOFJBQQyp #JJDC portfolio
Open
Aetion Closes $110M Series C Funding Round Led by Warburg Pincus

Aetion Closes $110M Series C Funding Round Led by Warburg Pincus

/PRNewswire/ -- Health care technology company Aetion announced today a $110 million Series C fundraise, led by Warburg Pincus, a leading global growth equity...

@PearlF shared
On May 10, 2021
South SF-based @GladstoneInst spinout by @QB3 Therini Bio announced $17M seed from SV Health, Merck/MRL Ventures, Sanofi Ventures, Dolby & Dementia Discovery Fund 2continue development of fibrin antibody therapeutics based on tech from @AkassoglouLab https://t.co/CGEVdfZT7Y.
Open
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic

Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic

/PRNewswire/ -- Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development...

@BentheFidler shared
On May 13, 2021
Third Rock launches #biotech targeting 'notoriously difficult' DNA regulators https://t.co/Yk6wAjFwut By @realjacobbell #startups @ThirdRockV
Open
Third Rock launches biotech targeting 'notoriously difficult' DNA regulators

Third Rock launches biotech targeting 'notoriously difficult' DNA regulators

With $82 million in hand, Flare Therapeutics is looking to create precision cancer drugs by going after a type of protein called transcription factors.

@IAmBiotech shared
On May 12, 2021
#GoodDayBIO: We’re unpacking two critical global trade issues: IP protections for COVID-19 vaccines and Mexico’s response to gene-edited agricultural products, specifically corn. https://t.co/vgzXNaRp6h
Open
Price controls, patent waivers, and Mexico's biotech policies

Price controls, patent waivers, and Mexico's biotech policies

Ahead of congressional hearings today and tomorrow on the Biden administration’s trade policy agenda, we’re unpacking two critical global trade issues: IP protections for COVID-19 vaccines ...

@FierceBiotech shared
On May 12, 2021
Now, at Gennao Bio, he’s back in biotech management, after being an interim CEO at Passage Bio, another genetic medicines company he helped found via OrbiMed https://t.co/BQg0YnZBGP
Open
Alexion founder Squinto helms OrbiMed-backed startup with some Yale gene therapy tech

Alexion founder Squinto helms OrbiMed-backed startup with some Yale gene therapy tech

OrbiMed’s executive partner and a founder of rare disease biopharma Alexion (now AstraZeneca), Stephen Squinto, Ph.D., is taking the reins at non-viral gene therapy biotech Gennao Bio.

Read more: Startups
weekly 13.05.2021
View archives
Back to home

Subscribe to Biotech Essentials - Startups.

POPUP.POPUP_INTRO Biotech Essentials - Startups.
Privacy Policy

Sign up for the weekly Biotech Essentials - Startups newsletter

Never again miss anything or anyone that matter Biotech Essentials

Sign up and receive the Biotech Essentials - Startups weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy